SCHEMBL25754985

SCHEMBL25754985

CNC(=O)CCCCCCCCc1cscn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.40
HDAC1 Q13547 8/20 0.37
MTNR1A P48039 1/20 0.36
HDAC3 O15379 4/20 0.36
HDAC6 Q9UBN7 4/20 0.36
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
NAMPT P43490 1/20 0.35
FAAH O00519 2/20 0.34
TBK1 Q9UHD2 1/20 0.34
PKM P14618 1/20 0.34
HDAC2 Q92769 3/20 0.34
ALOX5 P09917 1/20 0.33
PDE5A O76074 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754983 0.88 GAA (0.33) TBXAS1HDAC1MTNR1AHDAC3HDAC6
SCHEMBL25754984 0.86 GAA (0.35) TBXAS1HDAC1HDAC3HDAC6MAPK1
SCHEMBL7186166 0.81 TBXAS1 (0.45) TBXAS1FAAH
SCHEMBL7782045 0.80 HPGD (0.43) MAPK1NPSR1KDM4C
SCHEMBL23118696 0.77 MAPK1 (0.47) MAPK1NPSR1KDM4CPKM
SCHEMBL25754765 0.76 MAPT (0.37) MAPK1NPSR1KDM4CPKM
SCHEMBL7281500 0.75 EPHX2 (0.52) FAAH
SCHEMBL4779862 0.74 PKM (0.42) MAPK1NPSR1KDM4CPKM
SCHEMBL18531931 0.73 KCNH2 (0.47) TBXAS1
SCHEMBL7439199 0.73 KCNH2 (0.47) TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 TBXAS1 3771/4885HDAC1 596/4885MTNR1A 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.